U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H28N2O2S
Molecular Weight 372.524
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-4455242 FREE BASE

SMILES

CC(C)CNCC1=CC=C(C=C1)C2=CC=CC=C2S(=O)(=O)N3CCCC3

InChI

InChIKey=OWVIKBRKPCTDEP-UHFFFAOYSA-N
InChI=1S/C21H28N2O2S/c1-17(2)15-22-16-18-9-11-19(12-10-18)20-7-3-4-8-21(20)26(24,25)23-13-5-6-14-23/h3-4,7-12,17,22H,5-6,13-16H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C21H28N2O2S
Molecular Weight 372.524
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800030611

Pfizer was developing PF-4455242, a selective, short-acting (non-"inactivating") antagonist of the κ-opioid receptor. PF-4455242 was pursued in phase I clinical trial for the treatment of the bipolar disorder and was also investigated as a treatment for depression and substance abuse. In September 2010 Pfizer discontinued the development of the compound.

CNS Activity

Originator

Pfizer
420
Curator's Comment: # Pfizer

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 10.0 nM [Ki]
Antagonist
2778
 1.23 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase I
428
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242).
2011 Aug 25
Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
2011 Nov

Sample Use Guides

In Vivo Use Guide
Single dose of up to 30 mg PF-4455242, delivered in capsule.
Route of Administration: Oral
In Vitro Use Guide
PF-4455242 bound with high affinity to human KOR stably expressed in CHO cells with an average Ki value of 3.0 nM
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:42:52 GMT 2023
Edited
by admin
on Sat Dec 16 01:42:52 GMT 2023
Record UNII
Y3530Z78QD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PF-4455242 FREE BASE
Common Name English
(1,1'-BIPHENYL)-4-METHANAMINE, N-(2-METHYLPROPYL)-2'-(1-PYRROLIDINYLSULFONYL)-
Systematic Name English
Code System Code Type Description
PUBCHEM
44599828
Created by admin on Sat Dec 16 01:42:52 GMT 2023 , Edited by admin on Sat Dec 16 01:42:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID30152783
Created by admin on Sat Dec 16 01:42:52 GMT 2023 , Edited by admin on Sat Dec 16 01:42:52 GMT 2023
PRIMARY
FDA UNII
Y3530Z78QD
Created by admin on Sat Dec 16 01:42:52 GMT 2023 , Edited by admin on Sat Dec 16 01:42:52 GMT 2023
PRIMARY
CAS
1202647-54-8
Created by admin on Sat Dec 16 01:42:52 GMT 2023 , Edited by admin on Sat Dec 16 01:42:52 GMT 2023
PRIMARY
Related Record Type Details
Structure of PF-4455242
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of PF-4455242 FREE BASE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966